You are here:
26 April 2021 / deal

Lauxera Capital Partners invests in LUMICKS

LUMICKS, a leading, next generation life science tools company that develops highly innovative platforms for Dynamic Single-Molecule and Cell Avidity analysis, announced the completion of a $93 million Series D preferred share financing.

Lauxera Capital Partners invests in LUMICKS

The funding round was led by new investors Farallon Capital Management and Lauxera Capital Partners, and included investments by Softbank Vision 2i, funds and accounts advised by T. Rowe Price Associates, Parian Global Management, Pura Vida Investments, and Irving Investors. The round was also backed by existing investor Gilde Healthcare and select members of the LUMICKS management team. A majority of the proceeds from the financing will be used to bolster growth initiatives including expansion of both research and development and commercial activities for the z-Movi® Cell Avidity Analyzer.



$800 million fundraise for MessageBird

US$800 million fundraise for MessageBird

This acquisition will intensify MessageBird’s focus on North America and tis competition with US rival Twilio Inc. read more
IFLR Awards 2021 Europe

IFLR Europe 2021 Award “Debt and Equity-Linked Deal of the Year”

Loyens & Loeff won for advising Novartis with the offering of EUR 1.85 billion 0.000% Sustainability-Linked Notes due 2028. read more
How should you change your pension scheme with effect from 1 January 2022?

How should you change your pension scheme?

At the end of last year, the draft bill for the Future of Pensions Act (Wet toekomst pensioenen) was published. read more